PHGE

BiomX Inc.

0.32 USD
-0.01 (-4.46%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

BiomX Inc. stock is down -5.59% since 30 days ago. The next earnings date is Aug 7, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 5 June’s closed higher than May. 100% of analysts rate it a buy.

About BiomX Inc.

BiomX Inc. develops products using natural and engineered phage technologies to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC) The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S.Aureus), a bacteria associated

  • Laidlaw & Co.
    Tue May 28, 11:34
    buy
    initial
  • HC Wainwright & Co.
    Tue May 21, 11:37
    buy
    confirm